Final Program

WEDNESDAY • MAY 18 393
Objectives
At the conclusion of this session, the participant will be able to:
• learn about current deep-phenotyping of PH;
• understand and learn pediatrics PH registry;
• learn about the national biorepository of PH patient samples for PH research.
Pulmonary hypertension (PH) currently has no cure, thus PH research remains a
high priority for NHLBI. Recently, NHLBI launched several major multi-center
clinical studies of PH including: Redefining Pulmonary Hypertension through
Pulmonary Vascular Disease Phenomics (PVDOMICS); and Pulmonary
Hypertension Breakthrough Initiative (PHBI), which will help us understand the
molecular mechanisms of PH in adult patients, and provide phenotypic data and
biomarkers for future clinical trials and measures of disease severity. Data Fusion:
A Sustainable, Scalable, Open Source Registry Advancing PVD Research using a
novel biomedical informatics approach will develop computable phenotypes of
pediatric pulmonary vascular diseases. This session will introduce these programs
and present data from these studies
Chairing: L. Xiao, MD, PhD, Bethesda, MD
C.J. Blaisdell, MD, Bethesda, MD
12:15 NHLBI PVDOMICS Program Overview
S.C. Erzurum, MD, Cleveland, OH
12:25 PVDOMICS Study Design and Update
J.H. Newman, MD, Nashville, TN
12:35 Data Fusion: A Sustainable, Open Source Registry Advancing
Pediatric Pulmonary Vascular Disease Research - Part I
S.H. Abman, MD, Aurora, CO
12:45 Data Fusion: A Sustainable, Open Source Registry Advancing
Pediatric Pulmonary Vascular Disease Research - Part II
K. Mandl, MD, MPH, Boston, MA
12:55 Pulmonary Hypertension Breakthrough Initiative (PHBI) Update
M. Geraci, MD, Indianapolis, IN
1:05 National Biological Sample and Data Repository for Pulmonary
Arterial Hypertension
W. Nichols, PhD, Cincinnati, OH
L27
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
OXIDANT STRESS IN HIV-RELATED CHRONIC
LUNG DISEASE
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)
Target Audience
Providers of lung health; medical fellows in training; graduate post-doctoral
fellows; established scientists in basic research on lung biology, HIV
pathogenesis and infection disease.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the role of oxidative stress in the onset of lung diseases
associated with HIV infection in the HAART era;
• improve target possibilities for treating lung inflammatory diseases such as
pulmonary hypertension in HAART treated HIV patients;
• learn new findings about the role of oxidative stress in the onset of lung
complications in HIV (+) patients undergoing ART.
HIV-infected patients on antiretroviral therapy (ART) have now a longer life
expectancy, but as a consequence chronic diseases are increasingly becoming
a major cause of morbidity and death. Many pulmonary conditions, including
PAH, and COPD are more prevalent in HIV infected individuals under treatment
but the mechanisms by which HIV and ART induce cellular dysfunction that may
trigger these pathologies are largely unknown. One such pathway is oxidative
stress (OS), which results from excessive free radical production, and
exceeding endogenous antioxidant defense mechanisms, which can damage a
wide variety of cellular components. The session will address current research
and results in this area and will give an overview of current HIV research on the
oxidative stress role in HIV infection. Presenters will delineate current
knowledge of lung complications in relationship to OS, and describe latest
results and techniques utilized in their projects.
Chairing: H.L. Twigg, MD, Indianapolis, IN
E. Caler, PhD, Bethesda, MD
12:15 HIV Proteins and Pulmonary Hypertension
S. Flores, PhD, Aurora, CO
12:30 Oxidative Stress in HIV Associated COPD
B.D. Medoff, MD, Boston, MA
12:45 Redox Stress and Chronic Lung Disease in HIV
J. Roman, MD, Louisville, KY
1:00 HIV+ Alveolar Macrophage Oxidant-Mediated Apoptosis of
Pulmonary Endothelium
M.R. Staudt, PhD, New York, NY
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH
L28 NHLBI PETAL CLINICAL TRIAL NETWORK:
PREVENTION AND EARLY TREATMENT OF ACUTE
LUNG INJURY
12:15 p.m. - 1:15 p.m. MOSCONE CENTER
Room 2020/2022 (West Building, Level 2)
Target Audience
Practicing critical care and emergency medicine clinicians and clinical
researchers would benefit from this session. This includes fellows, students,
nurses, and other medical professionals. Persons interested in clinical trial
design and conduct would also benefit from this session.
Objectives
At the conclusion of this session, the participant will be able to:
• understand the goals and structure of the PETAL network
• understand the questions being addressed in PETAL and outreach efforts of the
network
• have a better understanding of PETAL trial design and conduct including
utilization of a central IRB
WEDNESDAY MID-DAY
ATS 2016 • San Francisco